Physician profile
Neil E Kramer
NPI 1316918535
$2,666.03
in general payments reported to CMS, 2019-2025
23 companies · $87.61 in 2025
The $87.61 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $315 · 2021: $527 · 2022: $375 · 2023: $191 · 2024: $174 · 2025: $87.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $479.12 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $412.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $393.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $339.41 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $142.01 | 2019-2022 | |
| Astellas Pharma US INC | $135.29 | 2019 | |
| Boston Scientific Corporation | $121.84 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $94.39 | 2020-2024 | Uptravi, Opsumit |
| Amgen INC. | $86.92 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.81 | 2019-2023 | Lifevest |
| Heartflow, INC. | $47.58 | 2025 | |
| Abbott Laboratories | $45.73 | 2021-2022 | |
| Gilead Sciences, INC. | $39.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.75 | 2019-2025 | Camzyos |
| Edwards Lifesciences Corporation | $37.24 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $36.79 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.88 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $23.71 | 2020-2021 | |
| Ekos Corporation | $21.87 | 2019 | |
| Medtronic Vascular, INC. | $17.19 | 2019 | |
| Amarin Pharma, INC. | $14.97 | 2019 | |
| Lilly USA, LLC | $14.82 | 2023 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $13.23 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.